Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 30 for “"MS-275"”.

  1. Clinical Pharmacology of MS-275, A Histone Deacetylase Inhibitor

    … vitro metabolism and plasma protein binding of MS-275, a novel histone deacetylase inhibitor, in patients with solid tumors and lymphomas. A validated LC/MS assay was developed to quantitate MS-275 in plasma, human liver microsomes and urine. The pharmacokinetic (PK) evaluation was done using a …

    vcu Repository record for Clinical Pharmacology of MS-275, A Histone Deacetylase Inhibitor (opens in a new tab)

  2. Protective effects and mechanisms of MS-275 on lipotoxicity in C2C12 myocyte

    … study, we investigated the molecular mechanisms underlying the protective effects of class I HDAC inhibition under lipotoxic conditions, i.e., in palmitate (PA)-treated C2C12 myotubes. Palmitate treatment of C2C12 muscle cells increased HDAC3 protein expressions, increased inflammatory …

    ajou Repository record for Protective effects and mechanisms of MS-275 on lipotoxicity in C2C12 myocyte (opens in a new tab) Embargoed until 9999-12-31

  3. MS-275 (ENTINOSTAT) PROMOTES SUSTAINED TUMOR REGRESSION IN THE CONTEXT OF BOOSTING ONCOLYTIC IMMUNOTHERAPY

    … that histone deacetylase (HDAC) inhibition with MS-275 in the context of boosting oncolytic immunotherapy can drive heightened antitumor responses, leading to increased survival in mouse intracranial melanoma models. However, it is currently unclear how the co-administration of MS-275 directly …

    mcmaster Repository record for MS-275 (ENTINOSTAT) PROMOTES SUSTAINED TUMOR REGRESSION IN THE CONTEXT OF BOOSTING ONCOLYTIC IMMUNOTHERAPY (opens in a new tab)

  4. Acetazolamide potentiates the anti-tumor efficacy of sulforaphane and HDAC inhibitor, MS-275, on bronchial carcinoids and neuroblastoma

    Bronchial carcinoids (BC) and neuroblastoma (NB) are subgroups of neuroendocrine tumors of the lung and peripheral nervous system, respectively. BC present mainly in adults, and NB in children. BC accounts for 1–5% of all invasive lung malignancies and the atypical variant has a poor prognosis. NB …

    toronto-retro Repository record for Acetazolamide potentiates the anti-tumor efficacy of sulforaphane and HDAC inhibitor, MS-275, on bronchial carcinoids and neuroblastoma (opens in a new tab)

  5. The Histone Deacetylase Inhibitor, Ms-275, Sensitizes Metastatic Osteosarcoma to Fasl-Induced Cell Death: A Role For C-Flip

    … effects of the histone deacetylase inhibitor, MS-275, on the Fas signaling pathway and susceptibility of osteosarcoma (OS) to Fas ligand (FasL)-induced cell death. OS metastasizes almost exclusively to the lungs. We have shown that Fas expression in OS cells is inversely correlated with their …

    uthsc Repository record for The Histone Deacetylase Inhibitor, Ms-275, Sensitizes Metastatic Osteosarcoma to Fasl-Induced Cell Death: A Role For C-Flip (opens in a new tab)

  6. Concomitant Delivery of Histone Deacetylase Inhibitor, MS-275, Enhances the Therapeutic Efficacy of Adoptive T Cell Therapy in Advanced Stage Solid Tumours

    … tumours. We have previously shown that HDACi, MS-275, can enhance the therapeutic capacity of a T cell-based therapy in an aggressive brain tumour model. In addition, concomitant delivery of MS-275 with ACT ensures durable cures through immunomodulatory mechanisms. Strikingly, concomitant …

    mcmaster Repository record for Concomitant Delivery of Histone Deacetylase Inhibitor, MS-275, Enhances the Therapeutic Efficacy of Adoptive T Cell Therapy in Advanced Stage Solid Tumours (opens in a new tab)

  7. Testing the therapeutic efficacy of vesicular stomatitis virus as a single agent or in combination with the histone deacetylase inhibitor, MS-275, in a mouse model of ovarian cancer

    Ovarian cancer is the fifth leading cause of cancer death in Canadian women. Current treatments lack long-teen therapeutic benefit, indicating a need for novel approaches. An interesting novel cancer therapeutic is the oncolytic virus, vesicular stomatitis virus (VSV), which has yielded promising …

    ottawa-retro Repository record for Testing the therapeutic efficacy of vesicular stomatitis virus as a single agent or in combination with the histone deacetylase inhibitor, MS-275, in a mouse model of ovarian cancer (opens in a new tab)

  8. Synergism of heat shock protein and histone deacetylase inhibitors in synovial sarcoma

    … of 17AAG with the histone deacetylase inhibitor MS-275 for synergism by performing proliferation and apoptosis assays on synovial sarcomas. Synergism was assessed by the median-effect principle of Chou and Talalay. The combination was found to be highly synergistic at multiple time points in both …

    ubc Repository record for Synergism of heat shock protein and histone deacetylase inhibitors in synovial sarcoma (opens in a new tab) Download PDF for Synergism of heat shock protein and histone deacetylase inhibitors in synovial sarcoma (opens in a new tab)

  9. Targeting B Cell Acute Lymphoblastic Leukemia with Oncolytic Virotherapy and Histone Deacetylase Inhibition

    … with HDIs in L1210 cells. Interestingly, MS-275 or SAHA in combination with the viral mimic imiquimod additively reduced L1210 cell viability. Hence, we hypothesize that OVs may sensitize B-ALL cells to HDI-mediated toxicity. In vivo, MG1 in combination with SAHA and MS-275 appeared to …

    guelph Repository record for Targeting B Cell Acute Lymphoblastic Leukemia with Oncolytic Virotherapy and Histone Deacetylase Inhibition (opens in a new tab)

  10. Induced Gene Expression In Bladder Cancer: Kindlin-2 And Metallothionein-1x

    … with bladder cancer. Metallothionein isoforms 1 & 2 (MT I/II) are over-expressed in high-grade muscle-invasive bladder cancers, and in one study, MT-1X showed increased levels of expression compared to the other isoforms. The main goal of the MT-1X study was to investigate the mechanism by …

    nodak Repository record for Induced Gene Expression In Bladder Cancer: Kindlin-2 And Metallothionein-1x (opens in a new tab)

  11. EPIGENETIC REGULATION OF CYTOSOLIC PHOSPHOLIPASE A2

    … trichostatin A, valproic acid, tubacin and MS-275 increased cPLA2a mRNA expression in SH-SY5Y cells. Co-treatment of the histone acetyltransferase inhibitor, anacardic acid, modulated upregulation of cPLA2a induced by TSA. Specific involvement of class I HDACs and HAT in cPLA2a regulation …

    nus Repository record for EPIGENETIC REGULATION OF CYTOSOLIC PHOSPHOLIPASE A2 (opens in a new tab) Download file for EPIGENETIC REGULATION OF CYTOSOLIC PHOSPHOLIPASE A2 (opens in a new tab)

  12. Harnessing Oncolytic Virus-mediated Anti-tumour Immunity

    … at McMaster University, I demonstrate that MS-275, but not SAHA, selectively depletes naïve and regulatory lymphocytes. Memory lymphocytes that are being boosted remain unscathed and even have enhanced cytokine production, potentially as a consequence of the depleted lymphocyte compartment. …

    ottawa-retro Repository record for Harnessing Oncolytic Virus-mediated Anti-tumour Immunity (opens in a new tab)

  13. Improving Adoptive Cell Therapy to Overcome Tumor Resistance

    … chemical inhibition of histone deacetylases via MS-275 (Entinostat) during ACT can subvert tumor resistance to foster potent, broad-spectrum antitumor immunity. Overall, the work described supports the efficacy of ACT in the treatment of immunosuppressive, solid tumors; however, consistency in …

    mcmaster Repository record for Improving Adoptive Cell Therapy to Overcome Tumor Resistance (opens in a new tab)

  14. Identifying Novel Inhibitors of Epithelial to Mesenchymal Transition (EMT) for Targeting Pancreatic Cancer Metastasis and Cancer Stem Cells

    … localized disease have no recognizable symptoms. As a result, more than half of the patients with this disease are diagnosed at a stage where metastases have developed, for whom the overall 5-year survival is only 2%. Moreover, these tumors are highly enriched with a cancer stem cell (CSC) …

    ku Repository record for Identifying Novel Inhibitors of Epithelial to Mesenchymal Transition (EMT) for Targeting Pancreatic Cancer Metastasis and Cancer Stem Cells (opens in a new tab)

  15. The effect of histone deacetylase inhibitors on SRC and BCL2L1 gene expression and a potential role for phosphatases in their transcriptional repression

    … was not seen following treatment with MS-275 and MGCD0103, although p21WAF1 mRNA expression was induced. ChIP experiments revealed that following HDACi treatment, histone acetylation levels and RNA Polymerase II occupancy increased in the promoter regions of both the SRC and BCL2L1 …

    sask Repository record for The effect of histone deacetylase inhibitors on SRC and BCL2L1 gene expression and a potential role for phosphatases in their transcriptional repression (opens in a new tab)

  16. Investigation of the Role of Histone Acetylation in Hippocampus-Dependent Memory Formation

    … Chapter 1 reviews the transcriptional mechanisms involved in the memory formation, including the contribution of chromatin modification by acetylation of histone proteins. Mutating the histone acetyltransferase CREB-binding protein (CBP) impairs long-term memory formation, and pharmacologically …

    penn Repository record for Investigation of the Role of Histone Acetylation in Hippocampus-Dependent Memory Formation (opens in a new tab)

  17. STUDY OF THE ROLE OF CLASS I HISTONE DEACETYLASES IN DIFFERENTIATION, METABOLISM AND IMMUNOPHENOTYPE OF ADIPOSE TISSUE

    … showed that inhibition of class I HDACs with MS-275, during early stage of adipocyte differentiation, leads to reduction of lipid droplets size. This phenomenon was accompanied by increased expression of genes regarding adipocyte functionality, lipolysis and fatty acid β-oxidation. However, …

    milano Repository record for STUDY OF THE ROLE OF CLASS I HISTONE DEACETYLASES IN DIFFERENTIATION, METABOLISM AND IMMUNOPHENOTYPE OF ADIPOSE TISSUE (opens in a new tab)

  18. Targeting histone deacetylases to suppress bone loss in similar chronic inflammatory diseases, periodontitis and rheumatoid arthritis.

    … and our growing knowledge of the mechanisms involved in the disease processes, the control of bone destruction is still a challenging problem. For this reason it is important to identify anti-resorptive agents that may also inhibit inflammation which can be delivered orally upon diagnosis. …

    adelaide Repository record for Targeting histone deacetylases to suppress bone loss in similar chronic inflammatory diseases, periodontitis and rheumatoid arthritis. (opens in a new tab)

  19. Can changes in SR protein acetylation affect alternative splicing?

    … (HDAC) inhibition, using the HDAC inhibitors MS-275 and SAHA. RNA from treated cells was isolated for use with RT-PCR arrays developed by Peter Stoilov. Western blotting was used to determine efficacy of HDAC inhibitors on total cellular acetylation. The future goal is to understand how …

    wvu Repository record for Can changes in SR protein acetylation affect alternative splicing? (opens in a new tab)

Page 1 of 2